Abstract:The EphB4 receptor tyrosine kinase together with its preferred ligand, ephrin-B2, regulates a variety of physiological and pathological processes, including tumor progression, pathological forms of angiogenesis, cardiomyocyte differentiation and bone remodeling. We previously reported the identification of TNYL-RAW, a 15 amino acid-long peptide that binds to the ephrin-binding pocked of EphB4 with low nanomolar affinity and inhibits ephrin-B2 binding. Although ephrin-B2 interacts promiscuously with all the EphB receptors, the TNYL-RAW peptide is remarkably selective and only binds to EphB4. Therefore, this peptide is a useful tool for studying the biological functions of EphB4 and for imaging EphB4-expressing tumors. Furthermore, TNYL-RAW could be useful for treating pathologies involving EphB4-ephrin-B2 interaction. However, the peptide has a very short half-life in cell culture and in the mouse blood circulation due to proteolytic degradation and clearance by the kidneys and reticuloendothelial system. To overcome these limitations, we have modified TNYL-RAW by fusion with the Fc portion of human IgG1, complexation with streptavidin or covalent coupling to a 40 KDa branched polyethylene glycol (PEG) polymer. These modified forms of TNYL-RAW all have greatly increased stability in cell culture, while retaining high binding affinity for EphB4. Furthermore, PEGylation most effectively increases peptide half-life in vivo. Consistent with increased stability, submicromolar concentrations of PEGylated TNYL-RAW effectively impair EphB4 activation by ephrin-B2 in cultured B16 melanoma cells as well as capillary-like tube formation and capillary sprouting in co-cultures of endothelial and epicardial mesothelial cells. Therefore, PEGylated TNYL-RAW may be useful for inhibiting pathological forms of angiogenesis through a novel mechanism involving disruption of EphB4-ephrin-B2 interactions between endothelial cells and supporting perivascular mesenchymal cells. Furthermore, the PEGylated peptide is suitable for other cell culture and in vivo applications requiring prolonged EphB4 receptor targeting.

Computational Design Of Antiangiogenic Peptibody By Fusing Human Igg1 Fc Fragment And Hrh Peptide: Structural Modeling, Energetic Analysis, And Dynamics Simulation Of Its Binding Potency To Vegf Receptor

The Design, Characterizations, and Tumor Angiogenesis Inhibition of a Multi-Epitope Peptibody with Bfgf/vegfa

A Novel Peptide Specifically Binding to VEGF Receptor Suppresses Angiogenesis in Vitro and in Vivo

Optimized Expression And Characterization Of A Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 And Programmed Death-1 In Pichia Pastoris And Evaluation Of Antitumor Activity In Vivo

De Novo Computational Design for Development of a Peptide Ligand Oriented to VEGFR-3 with High Affinity and Long Circulation.

Applying computational protein design to engineer affibodies for affinity-controlled delivery of vascular endothelial growth factor and platelet-derived growth factor

Pegylation Potentiates The Effectiveness Of An Antagonistic Peptide That Targets The Ephb4 Receptor With Nanomolar Affinity

Structure-Guided Discovery of PD-1/PD-L1 Interaction Inhibitors: Peptide Design, Screening, and Optimization via Computation-Aided Phage Display Engineering

Structural insights into molecular-targeting helix-loop-helix peptide against vascular endothelial growth factor-A

[Inhibition of tumor growth by a peptide fusion protein binding to vascular endothelial growth factor receptor Flt-1]

Design and Evaluation of Α-Helix-based Peptide Inhibitors for Blocking PD-1/PD-L1 Interaction.

A Frog-Derived Bionic Peptide With Discriminative Inhibition Of Tumors Based On Integrin Alpha V Beta 3 Identification

Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis.

Structure-based Design, Synthesis and Evaluation of Bioactivity of Anti-P-gp Peptide Mimetic

In Silico Exploration and Biological Evaluation of Bispecific Peptides Derived from Anti-HER2 Antibodies and Peptide-Camptothecin Conjugates for HER2-Positive Breast Cancer

Inhibition of Angiogenesis by a Novel Small Peptide Consisting of the Active Fragments of Platelet Factor-4 and Vasostatin

Identification Of Vegfr2-Binding Peptides Using High Throughput Bacterial Display Methods And Functional Assessment

Computational Design And Optimization Of Novel D-Peptide Tnf Alpha Inhibitors

Molecular Design of Peptide-Fc Fusion Drugs.

Large-scale Production, Purification, and Function of a Tumor Multi-Epitope Vaccine: Peptibody with Bfgf/vegfa

A Synthetic Bivalent Peptide Ligand of EphB4 with Potent Agonistic Activity